Statistics, trend data, and financial figures in this article are illustrative examples created for educational purposes. They may not reflect actual market conditions. Always verify data against authoritative sources.
We're three months into 2026, and one pattern is hard to ignore: CEOs are buying their own stock at a pace we haven't seen since the 2022 market correction. Across our filtered dataset of C-suite open-market purchases, Q1 2026 activity is running 23% above the 5-year quarterly average.
Here's what the data shows, which sectors are driving the activity, and what it could mean for the broader market.
Q1 2026 by the numbers
The total dollar volume of CEO open-market purchases in Q1 2026 is on pace to reach an estimated $318M — the highest quarterly figure in our dataset going back to 2024. This includes only purchases by chief executives and chief financial officers of publicly traded companies, filtered for open-market transactions only.
Sector breakdown: Where the smart money is going
The sector distribution of CEO purchases tells a story about where insiders see value:
Healthcare leads for the second straight quarter
Healthcare CEOs have been the most aggressive buyers, accounting for 28% of total purchase volume. This is notable because the healthcare sector (XLV) is down 8% year-to-date — the worst performing major sector. CEO buying into sector weakness is a classic contrarian signal.
The concentration is particularly strong in mid-cap biotech and medical devices, where several companies are trading below 15x forward earnings despite double-digit revenue growth. CEOs appear to be signaling that the market is over-penalizing the sector for regulatory uncertainty.
Financials: Regional bank CEOs are loading up
At 22% of total volume, financial sector CEO purchases are running at 2x their 2025 average. Most of this activity is concentrated in regional banks with $5B–$50B in assets. The pattern suggests regional bank executives see the current rate environment as favorable for net interest margin expansion, even as the broader market remains skeptical about credit quality.
Technology: Selective, not broad
Unlike the broad-based buying in healthcare and financials, tech CEO purchases are concentrated in specific niches: enterprise software, cybersecurity, and AI infrastructure. Consumer tech and SaaS growth names are notably absent — CEO buying activity in those subsectors remains at multi-year lows.
Average deal sizes are increasing
| Period | Avg. Purchase | Median Purchase | Count |
|---|---|---|---|
| Q1 2025 | $412K | $185K | 481 |
| Q2 2025 | $378K | $162K | 455 |
| Q3 2025 | $445K | $201K | 508 |
| Q4 2025 | $489K | $218K | 519 |
| Q1 2026* | $571K | $264K | 557 |
Both the average and median purchase sizes are at 2-year highs. This matters because larger purchases generally indicate stronger conviction. When CEOs are not only buying more frequently but also deploying more capital per transaction, it suggests a higher collective confidence level.
Historical context: What elevated insider buying has predicted
Historically, quarters with above-average insider buying activity have preceded above-average market returns:
- Q4 2022 saw a spike in CEO purchases during the market bottom. The S&P 500 went on to return 26% over the following 12 months.
- Q1 2020 (pandemic crash) saw extreme insider buying. The S&P 500 returned 56% from the March 2020 low over the next 12 months.
- Q4 2018 (rate hike scare) showed a similar pattern, followed by a 31% market return.
The correlation isn't perfect — insider buying is a leading indicator, not a guarantee. But the pattern is consistent enough that elevated buying activity is worth monitoring as a macro sentiment signal.
Aggregate insider buying activity is a useful macro gauge, but individual stock selection still matters enormously. A rising tide of insider buying doesn't mean every CEO purchase will outperform. The analysis layer — evaluating fundamentals, financials, and technicals for each signal — is what separates a data point from an investment thesis.
Three patterns to watch for the rest of 2026
1. Healthcare sector reversal
The concentration of CEO buying in healthcare, combined with sector underperformance, creates conditions for a mean-reversion trade. If regulatory clarity improves mid-year, the sector could see a sharp re-rating. Insider buying is often 3–6 months early.
2. Regional bank earnings acceleration
The aggressive buying by regional bank CEOs suggests they see NIM expansion that hasn't hit consensus estimates yet. Q1 and Q2 earnings season will be the litmus test. If these CEOs are right, the KRE (regional bank ETF) could outperform significantly in H2 2026.
3. Small-cap over large-cap rotation
Insider buying is disproportionately concentrated in companies with market caps under $10B. Large-cap CEO purchases remain muted. This suggests insiders see better value in smaller names — a pattern that historically precedes small-cap outperformance periods.
Bottom line
CEO stock purchases in 2026 are sending a clear signal: insiders are more bullish than the market. The elevated buying activity, increasing deal sizes, and sector concentration in beaten-down areas (healthcare, regional banks) suggest these executives see value the market hasn't priced in yet.
Whether you're actively trading insider signals or using them as a confirmation layer in your existing strategy, Q1 2026's data is hard to ignore.